1-9 of 9
Renee Ward, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Study of LY3410738, a First-in-Class Covalent Inhibitor of Mutant IDH in Advanced Myeloid Malignancies (Trial in Progress)

Eytan M. Stein, MD, Marina Konopleva, MD PhD, Raymond Gilmour, BSc, PhD, Anna M Szpurka, PhD, Elizabeth Hill, PhD, Renee Ward, MD PhD, Hagop M. Kantarjian, MD, Courtney D. Dinardo, MDMSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 26.
https://doi.org/10.1182/blood-2020-134307
Published: 2020
Journal Articles

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

John N. Allan, MD, Krish Patel, MD, Anthony R. Mato, MDMSCE, William G. Wierda, MD PhD, Javier Pinilla Ibarz, MD PhD, Michael Y. Choi, MD, Susan M. O'Brien, MD, Jeff P. Sharman, MD, Mazyar Shadman, MD, Douglas E Gladstone, MD, Matthew S. Davids, MD, John M. Pagel, MD PhD DSc, Renee Ward, MD PhD, Gary Acton, MD, Pietro Taverna, PhD, Judith A. Fox, PhD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3041.
https://doi.org/10.1182/blood-2019-126286
Published: 2019
Journal Articles

Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies

John N. Allan, MD, William G. Wierda, MD PhD, Krish Patel, MD, Susan M. O'Brien, MD, Anthony R Mato, MD, Matthew S Davids, Richard R. Furman, MD, John M. Pagel, MD PhD, Judith A. Fox, PhD, Renee Ward, MD PhD, Pietro Taverna, PhD, Jennifer R. Brown, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3141.
https://doi.org/10.1182/blood-2018-99-116382
Published: 2018
Journal Articles

First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects

Linda L. Neuman, MD MBA, Renee Ward, MD PhD, David Arnold, Daniel L. Combs, BS, Deena Gruver, MS, Wendy Hill, MBA, Josué Mfopou Kunjom, MD PhD, Langdon L. Miller, MD, Judith A. Fox, PhD
Journal: Blood
Blood (2016) 128 (22): 2032.
https://doi.org/10.1182/blood.V128.22.2032.2032
Published: 2016
Journal Articles

Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial

Farhad Ravandi, MD, Ellen K. Ritchie, MD, Hamid Sayar, MD, Jeffrey E. Lancet, MD, Michael Craig, MD, Norbert Vey, MD PhD, Stephen A. Strickland, Gary J. Schiller, MD, Elias J. Jabbour, MD, Harry P. Erba, MD PhD, Arnaud Pigneux, MD, Heinz-August Horst, MD PhD, Christian Recher, MD PhD, Virginia M. Klimek, MD, Jorge E. Cortes, MD, Gail J. Roboz, Adam R. Craig, MD PhD, Renee Ward, MD PhD, Jennifer Smith, PhD, Hagop M. Kantarjian, MD, Robert K. Stuart, MD
Journal: Blood
Blood (2016) 128 (22): 903.
https://doi.org/10.1182/blood.V128.22.903.903
Published: 2016
Journal Articles

Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR)

Farhad Ravandi, MD, Ellen Ritchie, MD, Hamid Sayar, MD, Jeffrey Lancet, MD, Michael D. Craig, MD, Norbert Vey, MD, Stephen A. Strickland, MD, Gary Schiller, MD, Elias Jabbour, MD, Harry P. Erba, MD PhD, Arnaud Pigneux, MD, Heinz-August Horst, MD, Christian Recher, MD, Virginia M. Klimek, MD, Jorge Cortes, MD, Eric J. Feldman, MD, Adam R. Craig, MD PhD, Judith A. Fox, PhD, Renee Ward, MD PhD, Jennifer Smith, PhD, Gary Acton, MD, Cyrus Mehta, PhD, Hagop M. Kantarjian, MD, Robert K Stuart, MD
Journal: Blood
Blood (2014) 124 (21): LBA-6.
https://doi.org/10.1182/blood.V124.21.LBA-6.LBA-6
Published: 2014
Journal Articles

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study

Guillermo Garcia-Manero, MD, Steven D. Gore, MD, Christopher R. Cogle, MD, Elias J. Jabbour, MD, M. Renee Ward, MD, PhD, Kyle J. MacBeth, PhD, Eric Laille, MS, Heidi Giordano, MA, Hagop M. Kantarjian, MD, Barry S. Skikne, MD
Journal: Blood
Blood (2010) 116 (21): 603.
https://doi.org/10.1182/blood.V116.21.603.603
Published: 2010
Journal Articles

A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.

Kyle J MacBeth, Eric Laille, Yuhong Ning, Christopher R. Cogle, MD, Barry Skikne, Steven D. Gore, MD, Guillermo Garcia-Manero, MD, M. Renee Ward, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1772.
https://doi.org/10.1182/blood.V114.22.1772.1772
Published: 2009
Journal Articles

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).

Guillermo Garcia-Manero, MD, Steven D. Gore, MD, Barry Skikne, Christopher R. Cogle, MD, Yuhong Ning, Kyle J MacBeth, Eric Laille, M. Renee Ward, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 117.
https://doi.org/10.1182/blood.V114.22.117.117
Published: 2009